$14.90—
NASDAQ
$14.90—
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain